Bromodomain protein

Show results for

Unknown (1274)
Genomics (625)
Transcriptomics (389)
Proteomics (83)
Other (24)
Methylation profiling (3)
Metabolomics (2)
Clinical (1)
Multiomics (1)

Organisms

Homo sapiens (438)
Mus musculus (153)
Aerococcus urinae NBRC 15544 = CCUG 36881 (60)
Andropogon gerardi (60)
Bacteria (60)
Bartonella quintana JK 31 (60)
Canis lupus familiaris (60)
Cnidaria (60)
Ectopseudomonas oleovorans CECT 5344 (60)
Ensifer adhaerens (60)
Globicatella sanguinis (60)
Halictus scabiosae (60)
Human immunodeficiency virus 1 (60)
Mesocricetus auratus (60)
Methylohalobius crimeensis 10Ki (60)
Miscanthus x giganteus (60)
Saccharomyces cerevisiae (13)
Drosophila melanogaster (8)
Plasmodium falciparum (8)
Arabidopsis thaliana (7)
Schizosaccharomyces pombe (6)
Plasmodium falciparum 3D7 (6)
Rattus norvegicus (6)
Caenorhabditis elegans (3)
Tetrahymena thermophila (2)
Gallus gallus (2)
Danio rerio (1)
Human gammaherpesvirus 8 (1)
Toxoplasma gondii (1)
Arabidopsis (1)

Organisms

Homo sapiens (252)
Mus musculus (78)
Saccharomyces cerevisiae (9)
Arabidopsis thaliana (5)
Rattus norvegicus (4)
Plasmodium falciparum (4)
Plasmodium falciparum 3D7 (3)
Toxoplasma gondii (3)
Tetrahymena thermophila (2)
Schizosaccharomyces pombe (2)
Drosophila melanogaster (2)
Pyropia haitanensis (1)

Repository

ENA (406)
geo (371)
biostudies-arrayexpress (247)
pride (60)
EGA (16)
MassIVE (13)
iProX (5)
jPOST (5)
MetaboLights (2)
ExpressionAtlas (1)

Tissue

Cell culture (18)
Brain (10)
Epithelial cell (7)
Embryonic stem cell (4)
Permanent cell line cell (4)
Fibroblast (3)
HEK-293T cell (2)
HeLa cell (2)
Heart (2)
Liver (2)
Myeloid cell (2)
Testis (2)
Blood cell (1)
Bronchoalveolar lavage (1)
Cerebellar neuron (1)
Cervix epithelium (1)
Chronic myeloid leukemia cell (1)
Early embryonic cell (1)
Embryo (1)
Epithelial cell of prostate (1)
Hepatocyte (1)
Kidney cell (1)
Lung (1)
MOLM-14 cell (1)
MOLM-16 cell (1)
MV-4-11 cell (1)
Spermatid (1)
Stomach (1)
TEX cell (1)
Whole body (1)

Disease

Acute leukemia (3)
Cervix carcinoma (3)
Hepatocellular carcinoma (2)
Respiratory syncytial virus infectious disease (2)
Testicular seminoma (1)
Embryonal carcinoma (1)
Carcinoma (1)
Brain glioblastoma multiforme (1)
COVID-19 (1)
Cardiovascular system disease (1)
Castration-resistant prostate carcinoma (1)
Disease free (1)
Endocervical adenocarcinoma (1)
Hepatitis D (1)
Malaria (1)
Melanoma (1)
Neuroblastoma (1)
Prostate adenocarcinoma (1)
Schizophrenia (1)
Substance abuse (1)

Technology Type

Mass Spectrometry (60)
Shotgun proteomics (29)
Affinity purification coupled with mass spectrometry proteomics (14)
Bottom-up proteomics (7)
Data-dependent acquisition (6)
Gel-based experiment (5)
SWATH MS (5)
Data-independent acquisition (3)
Chemical cross-linking coupled with mass spectrometry proteomics (2)
Illumina HiSeq 2500, Illumina MiSeq, NextSeq 500, Illumina HiSeq 2000 (1)
Illumina_Infinium_HumanMethylation450, Illumina_HumanHT-12v4 (1)
Illumina HiSeq 2000, ILLUMINA (1)
Mass spectrometry assay (1)
Mass spectrometry (1)
Affinity proteomics (1)
DiaPASEF (1)
Top-down proteomics (1)

Instrument Platform

NextSeq 500 (8)
Illumina HiSeq 4000 (6)
Q Exactive (4)
TripleTOF 5600 (4)
Illumina HiSeq 2500 (3)
Illumina NovaSeq 6000 (2)
Orbitrap Fusion Lumos (2)
Gene Titan (1)
Server unisa (1)
NextSeq 2000 (1)
Illumina HiSeq 2000 (1)
Illumina HiSeq 3000 (1)
LTQ Orbitrap Elite (1)
Orbitrap Eclipse (1)
Orbitrap Fusion (1)
Q Exactive HF (1)
Liquid Chromatography MS - alternating - reverse-phase (1)
Liquid Chromatography MS - alternating - hilic (1)
Liquid Chromatography MS - negative - reverse phase (1)

Publication Date

2016 (85)
2015 (71)
2014 (69)
2023 (65)
2025 (46)
2018 (43)
2022 (42)
2021 (40)
2026 (38)
2024 (37)
2013 (35)
2019 (35)
2020 (27)
2017 (27)
2012 (15)
2010 (9)
2011 (8)
2008 (4)
2009 (3)
2006 (1)
2005 (1)
2004 (1)

Metabolite Name

Hexenoylcarnitine (Car(6:1)) (1)
4-(Dimethylamino)pyridine (1)
1-Octadecylamine (1)
1-(1Z-Octadecenyl)-2-(4Z,7Z,10Z,13Z,16Z,19Z-docosahexaenoyl)-sn-glycero-3-phosphocholine (1)
1-Hexadecylamine (1)
2,4,6-Trimethylpyridine (1)
N-Oleoyl-D-erythro-sphingosylphosphorylcholine (1)
Oxotetradecadienoylcarnitine (Car(14:3-O)) (1)
1,2-Didocosahexaenoyl-sn-glycero-3-phosphocholine (1)
1-Palmitoyl-2-linoleoyl-sn-glycero-3-phosphocholine (1)
[(Aminocarbonyl)(methyl)amino]acetic acid (1)
2-(2-Aminoethoxy)acetic acid (1)
Tetradecenedioylcarnitine (Car(14:1-O2)) (1)
Alpinetin (1)
2-Amino-3-methyl-imidazo[4,5-f]quinoline (IQ) (1)
1-(1Z-Octadecenyl)-2-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-sn-glycero-3-phosphocholine (1)
1-O-Hexadecyl-2-O-(5Z,8Z,11Z,14Z,17Z-eicosapentaenoyl)-sn-glyceryl-3-phosphorylcholine (1)
1-Stearoyl-2-linoleoyl-sn-glycero-3-phosphocholine (1)
1-Docosahexaenoyl-2-stearoyl-sn-glycero-3-phosphocholine (1)
1-O-Hexadecyl-2-O-(4Z,7Z,10Z,13Z,16Z,19Z-docosahexaenoyl)-sn-glyceryl-3-phosphorylcholine (1)
.beta.-D-Glucopyranosiduronic acid, 4-(7-hydroxy-4-oxo-4H-1-benzopyran-3-yl)phenyl (1)
Hispidol (1)
Fenobucarb (1)
Picoline (1)
Decanoylcarnitine (Car(10:0)) (1)
Aminopicoline (1)
Cis-4-Decenoylcarnitine (1)
Octanoylcarnitine (Car(8:0)) (1)
Tiglylcarnitine (Car(5:1)) (1)
Cysteine S-sulfate (1)

First Public Date

2023 (54)
2025 (36)
2021 (36)
2022 (34)
2018 (33)
2026 (31)
2024 (31)
2019 (31)
2014 (30)
2016 (25)
2017 (24)
2020 (23)
2015 (15)
2013 (3)

Classification

protozoa (10)

Study status

Recruiting (1)

Study type

Transcription profiling by array (92)
ChIP-seq (79)
RNA-seq of coding RNA (59)
Other (4)
ChIP-chip by tiling array (3)
Methylation profiling by high throughput sequencing (2)
MRE-seq (1)
Unknown experiment type (1)
Animal - High-throughput sequencing (1)
ChIP-chip by array (1)
Genotyping by array (1)
ATAC-seq (1)
DNA-seq (1)
CUT&RUN (1)
Interventional (1)

Release Date

2022 (152)
2016 (138)
2023 (128)
2021 (120)
2024 (113)
2020 (106)
2015 (101)
2014 (100)
2018 (97)
2017 (92)
2019 (91)
2025 (89)
2013 (54)
2012 (32)
2026 (18)
2010 (17)
2011 (16)
2008 (14)
2009 (8)
2007 (6)
2000 (5)
2006 (4)
2004 (4)
2005 (3)
2002 (3)
2001 (3)
2003 (2)
1999 (1)
1997 (1)

Lab affiliation

Research Unit for Molecular Medicine, Department of clinical Medicine, Aarhus University, Aarhus, Denmark (5)
Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA (3)
Dept. of Molecular Biosciences, University of Texas at Austin, Texas 78712 USA (2)
EDyP (2)
Francis Crick Institute 1 Midland Road London NW1 1AT (2)
1Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC 27599, USA 2Department of Biochemistry and Biophysics, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC 27599, USA 3Curriculum in Genetics and Molecular Biology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA (1)
Biological Chemistry and Molecular Pharmacology, Harvard Medical School Cancer Biology, Dana-Farber Cancer Institute (1)
Biomolecular characterization unit, Center for Sustainable Resource Science, RIKEN (1)
CRCL UMR Inserm U1052, CNRS 5286, UCBL, CLB (1)
Cancer Epigenetics Group, Josep Carreras Leukaemia Research Institute, 08916, Badalona, Barcelona, Catalonia, Spain. (1)
Cancer Epigenetics Group, Josep Carreras Leukaemia Research Institute, 08916, Badalona, Barcelona, Catalonia, Spain (1)
Cardiac Bioengineering group, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia (1)
CeMM, Research Center for Molecular Medicine, Austrian Academy of Sciences, Austria (1)
Department of Biochemistry and Molecular Biology, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC29425, USA (1)
Department of Biochemistry and Molecular Biology, University of Maryland, Baltimore, MD 21201. Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, MD 21201. (1)
Department of Biological Sciences, Vanderbilt University (1)
Department of Molecular, Cellular, & Biomedical Sciences, Chu Lab, University of New Hampshire, United States (1)
Department of Pharmacology, University of Colorado School of Medicine, Aurora, CO 80045, USA (1)
Department of precious medicine, University of Campania "L.Vanvitelli", vico L. de Crecchio 8, Naples, Italy (1)
Director, Proteomics and Metabolomics Facility, Center for Open Research Resources and Equipment, University of Connecticut, Storrs, CT, USA (1)
EDyP team (1)
Facutly of Science, University of Geneva (1)
Georgetown University, USA (1)
Harvard Institutes of Medicine 2nd floor, Room 221 4 Blackfan Circle Boston, MA 02115 (1)
Institute for Clinical and Translational Research (ICTR), University of Wisconsin-Madison, Madison, WI, 53705, USA (1)
Institute for Clinical and Translational Research, University of Wisconsin - Madison (1)
Internal Medicine Morsani College of Medicine University of South Florida (1)
Laboratory of Cancer Metabolism, Department of Experimental Oncology, Maria Sklodowska-Curie National Research Institute of Oncology (1)
Laboratory of Systems Biology, University of Warsaw (1)
Medicinal Chemistry, Monash Institute of Pharmaceutica Science, Monash University, 381 Royal Parade, Parkville, Victoria 3052, Australia (1)

Location

United States (1)

Keyword

Capecitabine (1)

Previous page
1 / 241
You're on page 1
page 2
page 3
page 4
page 5
page ...
page 241
Next page

Sort by:

Relevance

Page size

Bromodomain-Containing-Protein 4 (BRD4) Regulates RNA Polymerase II Serine 2 Phosphorylation in Human CD4+ T Cells

Transcriptional elongation by RNA polymerase II (Pol II) is regulated by positive transcription elongation factor b (P-TEFb) in association with Bromodomain-containing protein 4 (BRD4). We used genome-wide chromatin immunoprecipitation sequencing in primary human CD4+ T cells to reveal that BRD4 co-...

ORGANISM(S): Homo sapiens

2012-11-14 | E-GEOD-33281 | biostudies-arrayexpress

The bromodomain protein BRD4 regulates splicing during heat shock

During heat stress cyto-protective genes including heat shock proteins are transcriptionally up-regulated and post-transcriptional splicing is inhibited. In contrast, co-transcriptional mRNA-splicing is maintained. These factors closely resemble the proteotoxic stress response during tumor developme...

ORGANISM(S): Homo sapiens

2016-09-07 | E-GEOD-73471 | biostudies-arrayexpress

Targeting MYCN in Neuroblastoma by BET Bromodomain Inhibition

Bromodomain inhibition comprises a promising therapeutic strategy in cancer, particularly for hematologic malignancies. To date, however, genomic biomarkers to direct clinical translation have been lacking. We conducted a cell-based screen of genetically-defined cancer cell lines using a prototypica...

ORGANISM(S): Homo sapiens

2013-02-25 | E-GEOD-43392 | biostudies-arrayexpress

Identification of a novel Bromodomain / Casein Kinase II / TAF-containing complex as a regulator of mitotic condensin function

ABSTRACT: Condensin is a central regulator of mitotic genome structure, with mutants showing poorly condensed chromosomes and profound segregation defects. Here we identify the fission yeast NCT complex, comprising the Nrc1 BET-family tandem bromodomain protein (SPAC631.02), Casein Kinase II (CKII) ...

ORGANISM(S): Schizosaccharomyces pombe

2014-01-10 | E-GEOD-53955 | biostudies-arrayexpress

Targeting the EWS/ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma

Ewing sarcomas (ES) are highly malignant, osteolytic bone or soft tissue tumors, which are characterized by early metastasis into lung and bone. Genetically, ES are defined by balanced chromosomal EWS/ETS translocations, which give rise to chimeric proteins (EWS-ETS) that generate an oncogenic trans...

ORGANISM(S): Homo sapiens

2015-12-08 | E-GEOD-72673 | biostudies-arrayexpress

Response and resistance to BET bromodomain inhibitors in triple negative breast cancer [ChIP-Seq]

Triple negative breast cancer (TNBC) is a heterogeneous and clinically aggressive disease for which there is no targeted therapy. Here we report the preferential and high sensitivity of TNBCs to BET bromodomain inhibitors such as JQ1 manifested by cell cycle arrest in early G1, apoptosis, and induct...

ORGANISM(S): Homo sapiens

2016-01-07 | E-GEOD-63581 | biostudies-arrayexpress

Response and resistance to BET bromodomain inhibitors in triple negative breast cancer [Chem-Seq]

ORGANISM(S): Homo sapiens

2016-01-07 | E-GEOD-63284 | biostudies-arrayexpress

Response and resistance to BET bromodomain inhibitors in triple negative breast cancer [RNA-Seq]

ORGANISM(S): Homo sapiens

2016-01-07 | E-GEOD-63582 | biostudies-arrayexpress

Bromodomain inhibition of the transcriptional coactivators CBP/EP300 as a therapeutic strategy to target the IRF4 network in multiple myeloma (ChIP-Seq)

Pharmacological inhibition of chromatin co-regulatory factors represents a clinically validated strategy to modulate oncogenic signaling through selective attenuation of gene expression. Here, we demonstrate that CBP/EP300 bromodomain inhibition preferentially abrogates the viability of multiple mye...

ORGANISM(S): Homo sapiens

2016-01-05 | E-GEOD-71909 | biostudies-arrayexpress

Therapeutic Targeting of BET Bromodomain Proteins in Castration-Resistant Prostate Cancer (microarray)

Men who develop metastatic castration-resistant prostate cancer (CRPC) invariably succumb to the disease. The development and progression to CRPC following androgen ablation therapy is predominantly driven by unregulated androgen receptor (AR) signaling1-3. Despite the success of recently approved...

ORGANISM(S): Homo sapiens

2014-04-25 | E-GEOD-55063 | biostudies-arrayexpress

Previous page
1 / 241
You're on page 1
page 2
page 3
page 4
page 5
page ...
page 241
Next page

Sort by:

Relevance

Page size

2401 Results

Show results for

Organisms

Organisms

Repository

Tissue

Disease

Technology Type

Instrument Platform

Publication Date

Metabolite Name

First Public Date

Classification

Study status

Study type

Release Date

Lab affiliation

Location

Tags

Keyword

OmicsDI is part of the ELIXIR infrastructure

Tweets